The Pennsylvania Department of Transportation (PennDOT) said pipe replacement is scheduled on Route 152 (Limekiln Pike/Main Street) in Hilltown and New Britain townships and Chalfont Borough, ...

A new study hints that Australia's first people arrived via a major northern route and a smaller southern route. Helen Farr and Erich Fisher, CC BY-NC-SA, via the Conversation Researchers have long ...

Kazakhstan will reroute some of the oil from at its giant Kashagan oilfield toward China after a Ukrainian drone attack on an export terminal on Russia’s Black Sea reduced loadings of Kazakh crude. At ...

PennDOT announced today that pipe replacement is scheduled on Route 152 (Limekiln Pike/Main Street) in Hilltown and New Britain townships and Chalfont Borough, Bucks County, beginning Monday, Dec. 15.

LAMAR, Mo. (KOAM) - The Missouri Department of Transportation (MoDOT) says a section of Route KK in Barton County will be closed Monday, Dec. 8, as crews replace a damaged pipe beneath the roadway.

Fulgent Genetics is rated Hold due to strong diagnostic revenue growth but an unproven transition into integrated precision medicine. FLGT's diagnostics business leads with rapid genome tests and ...

This is read by an automated voice. Please report any issues or inconsistencies here. A proposed pipeline from Phillips 66 and Kinder Morgan could end California’s status as a “fuel island.” The ...

CRISPR gives us the power to rewrite DNA, while AI accelerates that power beyond human control. Together, they’ve launched a genetic arms race that could redefine life—or erase it entirely. Marjorie ...

MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY). MeiraGTx will grant Lilly ...

Commuters in Miller are advised of an upcoming road closure as MoDOT crews conduct maintenance work next week. On November 12, from 8 a.m. to 4:30 p.m., 5th Street at Missouri Route 39 will be closed ...

After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced in ...